Obesity- Pharmacy Technician
The prevalence of obesity in the U.S. has increased dramatically over the past 20 years, doubling between 1980 and 2004. In 2009, only 1 state (Colorado) and the District of Columbia had a prevalence of obesity below 20%, and in 9 states the prevalence was 30% or greater. Among other conditions, obesity is directly linked to cardiovascular disease, type 2 diabetes, hypertension, osteoarthritis, and certain types of cancer. The health problems that accompany obesity lead to increased medical care and disability costs, which amounted to an estimated $147 billion in 2008. It is becoming clear that healthcare providers need to have a greater impact on this rising epidemic. This issue of The Rx Consultant will review the health consequences of obesity, current considerations in the evaluation of obesity, prescription medications linked with weight gain, the key components of weight loss education programs, FDA-approved medications for management (orlistat, phentermine, and diethylpropion), and considerations for patients who have undergone bariatric surgery. Medications recently rejected or removed from the market by the FDA are briefly discussed.